SCHEMBL4158038

SCHEMBL4158038

O=C(O)c1cnc2cc(F)ccc2c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.62
PDGFRB P09619 2/20 0.46
PDGFRA P16234 2/20 0.46
HCAR2 Q8TDS4 1/20 0.46
HPGDS O60760 4/20 0.44
PSMD14 O00487 1/20 0.43
MAP4K4 O95819 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
TRPM8 Q7Z2W7 3/20 0.42
HDAC3 O15379 2/20 0.41
EGLN1 Q9GZT9 1/20 0.41
GABRA1 P14867 1/20 0.41
BCL2L1 Q07817 1/20 0.40
BAD Q92934 1/20 0.40
P4HA1 P13674 1/20 0.40
P4HTM Q9NXG6 1/20 0.40
LDHA P00338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6086242 0.98 MGAM (0.60) MGAMPDGFRBPDGFRAHCAR2HPGDS
SCHEMBL845818 0.86 MGAM (0.62) MGAMPDGFRBPDGFRAHCAR2PSMD14
SCHEMBL30592049 0.85 HPGDS (0.61) MGAMPDGFRBPDGFRAHPGDSPSMD14
Hydrochloric Acid SCHEMBL6085748 0.85 MGAM (0.60) MGAMPDGFRBPDGFRAHCAR2PSMD14
SCHEMBL12686639 0.85 PDGFRB (0.45) MGAMPDGFRBPDGFRAHPGDSMAPT
SCHEMBL69368 0.84 MGAM (0.68) MGAMPDGFRBPDGFRAHPGDSPSMD14
SCHEMBL27701668 0.81 MGAM (0.60) MGAMPDGFRBPDGFRAHPGDSPSMD14
SCHEMBL1353291 0.81 MGAM (0.64) MGAMPDGFRBPDGFRAHPGDSPSMD14
SCHEMBL10473057 0.79 MGAM (0.62) MGAMHCAR2HPGDSPSMD14MAPT
SCHEMBL21063895 0.79 MGAM (0.62) MGAMPDGFRBPDGFRAHPGDSPSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324396-B2 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor AMGEN INC. (US) 2012-12-04 US claimed
US-20090054463-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor AMGEN INC. 2009-02-26 US claimed
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-29 US disclosed
WO-2025030163-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-02-06 WO disclosed
EP-3390384-B1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2021-09-15 EP disclosed
US-20210238162-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-05 US disclosed
EP-3390384-A1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS Astex Therapeutics Limited (GB) 2018-10-24 EP disclosed
WO-2017192304-A1 ARYLCARBOXAMIDES AND USES THEREOF INCEPTION 1, INC. (US) 2017-11-09 WO disclosed
WO-2017103851-A1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2017-06-22 WO disclosed
US-8324396-B2 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor AMGEN INC. (US) 2012-12-04 US disclosed
US-20090186918-A1 Triazole Compounds as Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2009-07-23 US disclosed
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 US disclosed
US-20090054463-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor AMGEN INC. 2009-02-26 US disclosed
EP-1943234-A1 TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS Biolipox AB (SE) 2008-07-16 EP disclosed
WO-2007051982-A1 TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS BIOLIPOX AB (SE) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054463-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor UTS2R, CASR, GPR17 MGAM 4137/4885PDGFRB 2805/4885PDGFRA 2250/4885
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS CSF1R, CSF3R, FLT3 MGAM 2202/4885PDGFRB 32/4885PDGFRA 27/4885
US-20210238162-A1 CHEMICAL COMPOUNDS HPGDS, PTGS1, PTGIS MGAM 3150/4885PDGFRB 285/4885PDGFRA 92/4885
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TRHR, TSHR MGAM 3011/4885PDGFRB 622/4885PDGFRA 905/4885
US-20090186918-A1 Triazole Compounds as Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 MGAM 2747/4885PDGFRB 2362/4885PDGFRA 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.